Intrauterine double-balloon tamponade vs gauze packing in the management of placenta previa
A multicentre randomized controlled trial

Jing Wei, MDa,b, Yimin Dai, MD, PhDa, Zhiqun Wang, MDb, Ning Gu, PhDb, Hongfang Ju, BSb, Youdi Xu, BSc, Biyun Xu, PhDb, Yali Hu, MD, PhDa,∗

Abstract
Background: To evaluate the effectiveness and safety of a newly designed intrauterine double-balloon catheter to arrest postpartum hemorrhage (PPH) following cesarean delivery (CD) for placenta previa.

Methods: We conducted an open-label, multicenter randomized controlled trial in two referral centers and one general hospital. Women with continuous bleeding after placental delivery following CD for placenta previa, who failed to respond to uterotonicus, suturing and uterine devascularization, and in the absence of suspected deeply invasive accreta were eligible subjects. Eligible subjects were randomized to receive intrauterine double-balloon catheter (n = 102) or gauze packing (n = 102). The main outcome was the rate of successful hemostasis without the need for additional surgical interventions. The secondary outcomes included the volume of blood loss during and after CD, the rate of PPH, incidence and amount of blood transfusion, hysterectomy, surgical complications, intensive care unit admission, need for re-laparotomy, length of hospital stay, and readmission.

Results: The 224 participants were recruited before delivery, with 20 excluded (14 cases bleeding stopped after uterotonicus and/or local myometrium sutures and 6 patients with placental increta). Finally, 102 women were assigned in catheter group and 102 others in gauze group. There was no difference in the rate of successful hemostasis in the catheter and gauze groups (93.1% vs 91.2%, P = .80). Compared with those in the gauze group, women in the catheter group showed significantly less blood loss within 24 hours postpartum (895 [612.3–1297.8] vs 1156 [882.5–1453.3] ml, P < .01), lower rate of PPH ≥1000 ml (42.2% vs 63.7%, P < .01). Accordingly, women in the catheter group had significantly less maternal adverse events such as postpartum anemia, puerperal morbidity, and postpartum pain.

Conclusion: Uterine tamponade using a double-balloon catheter was as effective as gauze packing in hemostasis, and appeared to be superior in reducing postpartum blood loss and pain following CD for placenta previa. Using double-balloon catheter in managing PPH in this situation may be a preferable alternative to minimize maternal morbidity.

Abbreviations: CD = cesarean delivery, PPH = postpartum hemorrhage.

Keywords: placenta previa, postpartum hemorrhage, uterine balloon tamponade

Editor: Daryle Wane.

Trial registration number: ChiCTR-ICR-15006467, http://www.chictr.org.cn

The author ZW and the corresponding author YH are the designers of the double-balloon catheter.

This study was performed according to the Declaration of Helsinki and approved by the institutional review boards of Nanjing Drum Tower Hospital (Approved No. of ethic committee: 2014-070-02). This study was supported by Jiangsu provincial key medical centre (no.2016004), and the National Key Clinical Department of Ministry of Health of China (20112271).

No further unpublished data are available. The full de-identified dataset had been submitted on http://www.medresman.org/uc/projectsh/projectlistauthor.aspx.

Supplemental Digital Content is available for this article.

© 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

How to cite this article: Wei J, Dai Y, Wang Z, Gu N, Ju H, Xu Y, Xu B, Hu Y. Intrauterine double-balloon tamponade vs gauze packing in the management of placenta previa: A multicentre randomised controlled trial. Medicine 2020;99:7(e19221).

Received: 17 November 2019 / Received in final form: 17 January 2020 / Accepted: 20 January 2020
http://dx.doi.org/10.1097/MD.0000000000019221
1. Introduction

Postpartum hemorrhage (PPH) following cesarean delivery (CD) for placenta previa is one of the leading causes of maternal morbidity and mortality.\[1] Approximately 10% of CD for placenta previa require intra- or post-operative blood transfusion, and ~4% requiring peripartum hysterectomy.\[2-4] In China, with the cessation of the national one-child policy implemented in previous decades, the incidence of placenta previa has been increasing due to more mature mothers, previous spontaneous or elective pregnancy terminations, and most importantly previous CD.\[5] While correct placental location prenatally allows for elective pregnancy terminations, the incidence of placenta previa has been increasing due to more mature mothers, previous spontaneous or elective pregnancy terminations, and most importantly previous CD.\[6] While correct placental location prenatally allows for individualized counseling and planning of the surgical management of the delivery,\[7] intrapartum and postpartum hemostasis at the lower uterine segment placenta site and related uterine atony remains a challenge.

Hemostasis at CD can be achieved with repeated doses of additional uterotonic, local suturing of the placental bed, uterine devascularization, or compression sutures such as the B-Lynch suture. In a resource-limited country such as China, uterine packing with gauge is a common practice to control PPH.\[6-7] In the 1980s, the idea of using an intrauterine balloon to produce a tamponade effect was introduced, and various types of balloon catheters have since been shown to produce similar successful rates of up to 91.5%.\[8] Owing to its simplicity, minimally invasive nature, and ease of application, balloon tamponade has become increasingly advocated as a first-line surgical intervention in the management of PPH to avoid more invasive interventions and hysterectomy.\[9-10] For placenta previa specifically, the use of the Bakri balloon, designed for the control bleeding from placenta previa, has decreased the rate of postpartum hysterectomy to less than a third of before.\[11] Nevertheless, the Bakri balloon can be associated with concealed bleeding, slide out of the uterine cavity easily, and even causing uterine perforation.\[12]

Our group has designed an intrauterine double-balloon catheter with a wide-bore drainage (Fig. 1A). Then we developed an operation procedure for intrauterine tamponade using our catheter. In this randomized controlled study, we compared the efficacy of the two tamponade technologies for hemostasis in our protocols in participants with continuous bleeding who had been failed after treating with conservative measures following CD for placenta previa.

2. Materials and methods

2.1. Design of the catheter

A double-balloon catheter for uterine tamponade was designed and developed in 2014. Following a pilot study,\[13] the catheter was modified and the final version is shown in Figure 1. The lower balloon was designed to generate direct pressure against the lower segment and internal os area which are the main bleeding sites in placenta previa. The upper balloon was designed to keep in the upper and middle uterine cavity for managing atony. The usual median total volume of the two balloons was 300 mL, which is comparable to the other balloons.\[13-16] During uterine closure, the lower balloon should be inflated first to pose local tamponade effect so as to reduce hemorrhage, and the partially inflated upper balloon provides room for visualization for the insertion of sutures to avoid catheter damaging. The gap between the two balloons avoids excessive pressure against the sutured incision from within which could lead to the suture cutting through the tissue after the balloons insufflated. The capsule caudal end facilitates trans-cervical insertion into the vagina (Fig. 1B, C). The stiffer large bore drainage tube design maintains patency by the implanted coil springs.

Since its introduction, the obstetricians participating in this study have been trained to apply this catheter successfully on many occasions. The development and adoption of this new balloon catheter in our institution is predominantly a cost issue, as it costs less than a third of the Bakri balloon catheter in China.

2.2. Trial design

This was a randomized controlled open-labelled study, conducted at three hospitals in Jiangsu province, China, between June 2015 and December 2017. The three hospitals have approximately 12,000 deliveries per annum, with PPH occurring in ~5.3% women following CD. Among these hospitals, Nanjing Drum Tower Hospital has ~7500 deliveries with 5.7% PPH, Taizhou People’s Hospital, ~3000 deliveries with 4.3% PPH, and Nanjing First Hospital, ~1500 deliveries with 5.1% PPH every year. Before enrollment, the study was registered at Chinese Clinical Trial Registry (ChiCTR-ICR-15006467). All the participating staff had been trained to follow the trial protocol (see online supplementary materials).

2.3. Patient and public involvement

Pregnant women were not involved in the design or conduct of the trial. The results of the trial will not be disseminated directly to participants.

2.4. Inclusion and exclusion criteria

Eligibility criteria included:
1) placenta previa diagnosed before delivery,
2) age ≥18 years,
3) gestation ≥28 weeks of pregnancy, and
4) requiring CD.

At recruitment, all the women provided a written informed consent. A transvaginal ultrasound scan confirmed the placental location not earlier than 2 weeks prior to the planned delivery. Exclusion criteria for the randomization included:
1) suspected deeply invasive placenta accreta,
2) fever above 38°C or chorioamnionitis at CD,
3) uterine malformation found at operation,
4) preoperative uterine artery embolisation,
5) uterine bleeding controlled following placenta delivery, after uterotonic and/or local myometrium sutures, or
6) the women had no desire to preserve the uterus.

2.5. Sample size and randomization

The estimated sample size was calculated based on the primary outcome of our previous pilot study and available data in the literature which showed that the rate of successful hemostasis was 97.7% by balloon tamponade, and 87.6% by gauze packing.\[17] Accordingly, 91 women per group were sufficient to show a difference of 10% in the successful rate as compared with the gauze with a 5% level of significance and a power of 80%. Considering the dropout rate of approximately 10%, finally, 102 women per arm were needed for randomization.
A computer-generated randomization code was produced and sequentially numbered. Block randomization with a 1:1 ratio for the double-balloon catheter or the gauze-roll group was set up with a block size of four. No stratification was performed. The numbers and codes were prepared and sealed in envelopes by a statistician of our institution before the trial. All the surgeons were blinded to the meaning of the numbers. During the CD, if tamponade method was decided, an envelope was opened by a nurse and revealed the allocation.

2.6. Intervention
CD was performed on lithotomy position and under spinal anesthesia. Uterine incision was encouraged to be made where feasible free of the placental edge. After fetal delivery and clamping of the umbilical cord, Carbetocin 100 μg (Ferring, St. Prex, Switzerland) was administered intravenously. The placenta was then removed by controlled cord traction. Manual separation would be performed in case of significant bleeding or suspected accreta. For controlling local bleeding from the
placental bed, second-line uterotonic drugs (Hemabate 250 μg, Pharmacia & Upjohn Company, Kalamazoo, MI) and multiple interrupted sutures were used. Ligation of the uterine vessels would be performed based on the operator’s judgement. If bleeding continued either from the placenta bed or due to atony, and regardless of the estimated blood loss at that point in time, tamponade method would be decided before any other interventions, and randomization was performed. For women allocated in the balloon catheter group (catheter group), the capsule caudal end of the device was inserted via the uterine incision through the cervix into and then retrieved from the vulvar end of the vagina by an assistant. Both the lower small and the upper large balloons were kept in the uterine cavity and in the end of the vagina by an assistant. Both the lower small and the upper large balloons were kept in the uterine cavity and inflated initially with 50 ml and 100 ml of sterile normal saline respectively for the tamponade test. If successful, the uterine incision was closed in 2 layers with non-locking continuous suture, the balloons were then further inflated (lower balloon usually to 50–100 ml, and upper balloon to 150–350 ml) until the uterus was considered ‘firm’. At the end of the procedure, the drainage port of the balloon was connected to a graduated collection bag to monitoring the amount of the bleeding.

For women in the gauze group, gauze rolls were packed in the cavity from the uterine fundus to the cervix with one end inserted into the vagina. Vaginal packing from posterior fornix to anterior fornix was placed afterwards to strengthen the compression to the lower uterine segment and maintain the position of the tamponade materials. If bleeding was continuous after tamponade, other additional measures were applied, including uterine artery embolization or hysterectomy. If bleeding was stopped, uterine and vaginal packing would be removed 12 to 24 hours later during day time. The Foley bladder catheter was kept in situ, and prophylactic antibiotic (cefazolin 1 g) was administered every 8 hours until the balloon or the gauze packing was removed. All the women were followed up to 6 weeks postpartum.

2.7. Outcomes

The primary outcome was the rate of successful hemostasis without the need for additional surgical interventions, involving artery embolization, hysterectomy, or replaced by another form of intruterine tamponade.

The secondary outcomes included the volume of blood loss during and after CD, the rate of PPH of ≥ 1000 ml and ≥ 1500 ml, the incidence and amount of blood transfusion, hysterectomy, the duration of the entire operation, surgical complications (such as vascular, bladder and bowel injury, and others), intensive care unit admission, the need of re-laparotomy, length of hospital stay, and readmission after discharge.

Blood loss was measured according to the volume aspirated by suction, the weight of drapes, sanitary pads, gauze retrieved from uterine/vaginal cavities, and blood collected by the drainage bag in milliliters within 24 hours postpartum. Tolerability of the procedure by the women was assessed by VAS (visual analog scale) pain scores. Adverse events, such as double-balloon rupture or puncture, intrauterine material expelled into vagina, uterine perforation or rupture, and difficulty in removal of the tamponade material, were recorded throughout the trial.

2.8. Statistical analyses

Primary and secondary outcomes were analyzed on an intention-to-treat analysis. To assess the difference in two groups, the student’s t-test, or Man-Whitney U test was used for continuous data depending on distribution, and the Chi-squared test or Fisher exact test where required was used for categorical data. Differences in proportions, medians (interquartile range) and mean (standard deviation) between the groups (with 95% confidence intervals) were also calculated, and adjusted for potential confounders where needed. A P value < .05 was considered statistically significant. Statistical analysis was performed using SPSS 20.0 (IBM, Armonk, NY).

3. Results

During the study period, 224 patients with placenta previa were recruited, in whom 14 patients stopped bleeding after uterotonics and/or local myometrium sutures and 6 patients complicated with placental increta, so those patients were excluded (Fig. 2). One of the participating hospitals, which is a non-referral general hospital, managed to randomize 3 participants in 2 years due to the difficulty in recruitment. We included these cases in the study because all three were managed strictly according to the randomization and the protocol.

Baseline demographic and obstetric characteristics were comparable between the 2 groups (Table 1), and the proportion of complete placenta previa was similar. Successful hemostasis without need for additional surgical intervention was 93.1% (95/102) in the catheter group and 91.2% (93/102) in the gauze group (P = .80, Table 2). Before uterine tamponade, blood loss was similar between the 2 groups. Following tamponade, the median blood loss in the catheter group was 895 ml (interquartile range 612.3–1297.8), significantly lower than that in the gauze group (1156 ml [interquartile range 882.5–1453.3], P < .01). The frequency of PPH ≥ 1000 ml in the catheter group was significantly lower than that in the gauze group (42.2% vs 63.7%, P < .01). However, the frequency of PPH ≥ 1500 ml had no difference between the two groups (14.7% vs 19.6%, P = .35).

In the catheter group, 23 (22.5%) of the 102 women achieved hemostasis by filling the lower balloon only, and 74 others (72.5%) achieved hemostasis by filling both lower and upper balloons. The median volume infused into the lower and upper balloons was 100 ml (50–105 ml) and 200 ml (150–250 ml) respectively. The operation time was similar in both groups. Significantly lower VAS score at 8 hours postpartum was found in the catheter group (20 [interquartile range 20–42.5] vs 30 [interquartile range 20–60], P < .01). Both balloon and gauze were kept in the uterus for a median duration of 21 hours.

For maternal complications (Table 2), compared with the women in the gauze group, the women in the catheter group had lower postpartum anemia rate (64.7% vs 82.4%, P < .01), and lower puerperal morbidity (9.9% vs 24.0%, P < .01). The 2 groups had no significant difference in the other outcomes (Table 2).

Regarding the incidence of adverse events (see online supplementary table S1, http://links.lww.com/MD/D801), 2 catheter balloons (2.1%) were inadvertently punctured by suturing needle, which were immediately replaced with new catheter balloons. Another catheter (1.0%) was expelled and passed into vagina, but the bleeding was subsequently controlled. Two cases (2.1%) in the gauze group had the gauze packing displaced into the vagina and led to massive bleeding; one was managed by balloon tamponade and the other was managed by artery embolization. No difficulty was encountered in removing the catheter, but, one case (1.0%) in the gauze group with...
displaced gauze had to have the gauze cut and pulled out under ultrasound guidance.

In all, 6 patients (2 in the catheter group, 4 in gauze group) failed to have bleeding arrested by tamponade. The details of those who required additional surgery are shown in online supplementary table S2, http://links.lww.com/MD/D802. Among them, 3 were procedure-related (insufficient tamponade) which had to be managed during or shortly after the operation. In 3 others, late-onset hemorrhage happened immediately after removing the tamponade materials (1 in catheter group, 2 in gauze group), and the bleeding was successfully arrested by artery embolization, or repeated double-balloon tamponade or hysterectomy respectively. There was no maternal death in either group.

4. Discussion

Uterine packing is recommended in some guidelines despite a paucity of analytical studies, and it is widely used currently in both rich and poor areas in China as recommended by our national institution. As balloon catheter has become increasingly popular in the control of PPH, it is becoming the recommended treatment. In a country like China, the cost of
commercially marketed balloon catheters such as the Bakri balloon has limited its clinical application. To date, no study was performed to compare the safety and efficacy of balloon tamponade with gauze packing. In the present study, we compared the safety and efficacy of our newly designed double-balloon catheter with traditional gauze packing in the management of placenta previa. Our results showed that, although either of balloon tamponade or gauze packing can achieve hemostasis in more than 90% of women, the women treated with balloon tamponade had less hemorrhage, lower incidence of PPH ≥1000 ml, decreased puerperal morbidity, and postpartum pain compared those treated with uterine gauze packing.

In previous reports, failure in the management of bleeding with balloon tamponade was attributed to damage or displacement of the balloon system.[21–23] In this trial, 3.1% of the catheters were punctured or expelled spontaneously under our protocol in which vaginal packing was placed. Furthermore, no severe adverse event, such as genital tract perforation or rupture, was observed in the study.

The timing of balloon catheter insertion remains a controversy. Considering the efficiency and convenience of the balloons, lowering the threshold for using balloon tamponade has been advocated.[23] A recent study found that severe blood loss before balloon tamponade increased the risks of procedure failure or treatment failure.[16] In this study, balloon tamponade was used much earlier following second-line uterotronics and indicated placenta bed sutures. Despite the fact that 80% of the women had complete placenta previa, there was less maternal morbidity and need for further interventions. In line with previous studies,[19,23] we considered that an earlier decision to use balloon tamponade could reduce the risk of PPH ≥1000 ml.

Our study was open-labelled randomized and implemented strictly following a pragmatic trial design. The measurement of blood loss was based on our previous and other researchers’ experience of using volume, weight as well as collecting bag. For accuracy, all commonly used drapes, absorbent pads, napkins, and gauze rolls were weighed before and after use, which enhanced the accuracy of blood loss estimation and the quality of the study.

### Table 2

Surgery and maternal outcomes according to treatment allocation.

| Outcome measure                              | Catheter group (n = 102) | Gauze group (n = 102) | Difference or OR (95% confidence interval) | Adjusted OR (95% confidence interval) | P value |
|----------------------------------------------|--------------------------|----------------------|------------------------------------------|---------------------------------------|---------|
| Without additional surgery, N (%)           | 95 (93.1)                | 93 (91.2)            | 1.31 (0.47–3.67)                         | 1.34 (0.47–3.85)                      | .80     |
| Estimated blood loss                         |                          |                      |                                          |                                      |         |
| During CS, median (IQR), ml                  | 675 (508.3–1092.5)       | 807 (537–1272.5)     | 42.5 (-50–147)                           | 1.07 (0.70–1.62)                      | .39     |
| ≥1000 ml before uterine packing, N (%)       | 32 (31.4)                | 30 (23.9)            | 1.07 (0.70–1.62)                         | 1.07 (0.57–2.00)                      | .76     |
| After uterine packing, median (IQR), ml      | 120 (70–182.5)           | 312.6 (223–450)      | 180 (146–212)                            | .01                                   | <.01    |
| Total amount of blood loss within 24 hrs.    | 293 (118–352.6)          | 1156 (882.5–1453.3)  |                                          |                                      | <.01    |
| postpartum, median (IQR), ml                 |                          |                      |                                          |                                      |         |
| Postpartum hemorrhage ≥1000 ml, N (%)        | 43 (42.2)                | 65 (63.7)            | 0.66 (0.51–0.87)                         | 0.38 (0.21–0.68)                      | <.01    |
| Postpartum hemorrhage ≥1500 ml, N (%)        | 15 (14.7)                | 20 (19.6)            | 0.75 (0.41–1.38)                         | 0.71 (0.33–1.52)                      | .35     |
| Procedures before uterine packing, N (%)     |                          |                      |                                          |                                      |         |
| Placental bed sutures                        | 67 (65.7)                | 65 (63.7)            | 1.03 (0.84–1.26)                         | 1.06 (0.59–1.92)                      | .77     |
| Ligation of uterine artery                   | 6 (5.9)                  | 6 (5.9)              | 1.00 (0.33–3.00)                         | 1.10 (0.33–3.63)                      | 1.00    |
| Second-line uterotronics                     | 65 (67.0)                | 73 (75.3)            | 0.89 (0.74–1.07)                         | 0.65 (0.35–1.22)                      | .21     |
| Duration of the entire surgery, median (IQR), min | 60 (50–70)               | 60 (50–72)           | 0 (5 to 5)                              | .97                                   |         |
| Additional hemostasis interventions after operation, N (%) | 0 (0)                   | 2 (2.1)              | N/A                                     | N/A                                   | .48     |
| Uterine double-balloon tamponade (if gauze arm) | 0 (0)                   | 2 (2.1)              | N/A                                     | N/A                                   | .48     |
| Uterine gauze packing (if balloon arm)       | N/A                      | N/A                  | N/A                                     | N/A                                   |         |
| Interventional radiology                     | 2 (2.0)                  | 1 (1.0)              | 2.00 (0.18–21.71)                        | 2.23 (0.19–26.93)                     | 1.00    |
| Re-exploratory & hysterectomy                | 0 (0)                    | 1 (1.0)              | N/A                                     | N/A                                   | 1.00    |
| Uterine packing management                   |                          |                      |                                          |                                      |         |
| Duration of packing, median (IQR), h.        | 21 (19–23)               | 21 (19–23)           | 0 (1–1)                                 | .93                                   |         |
| Expelled after placement, N (%)              | 1 (1.0)                  | 2 (2.0)              | 0.50 (0.04–4.43)                         | 0.47 (0.04–4.52)                      | 1.00    |
| Postpartum pain score at 8 h. (VAS score, median (IQR)) | 20 (10–42.0)            | 30 (20–60)           | 10 (0–10)                               | .01                                   |         |
| Maternal complications                       |                          |                      |                                          |                                      |         |
| Allogeneic transfusion, N (%)                | 37 (36.3)                | 36 (35.3)            | 1.03 (0.71–1.49)                         | 1.12 (0.62–2.04)                      | .88     |
| RBC transfusion ≥ 4.0 units, N (%)           | 17 (16.7)                | 13 (12.7)            | 1.31 (0.67–2.55)                         | 1.01 (0.42–2.39)                      | .43     |
| Coagulopathy, N (%)                          | 0 (0)                    | 3 (2.9)              | N/A                                     | N/A                                   | .25     |
| Intensive care unit admission, N (%)         | 0 (0)                    | 1 (1.0)              | N/A                                     | N/A                                   | 1.00    |
| Postpartum anemia , N (%)                    | 66 (64.7)                | 84 (82.4)            | 0.79 (0.66–0.93)                         | <.01                                  |         |
| Hemoglobin after 72 h. postpartum, mean (SD), g/L | 102.8 (15.6)             | 97.5 (15.0)          | −5.32 (−9.58 to −1.07)                   | .01                                   |         |
| Puerperal morbidity*, N (%)                  | 10 (9.9)                 | 24 (24.0)            | 0.41 (0.21–0.82)                         | 0.34 (0.15–0.77)                      | <.01    |
| Wound infection, N (%)                       | 1 (1.0)                  | 1 (1.0)              | 0.99 (0.06–15.61)                        | 1.02 (0.06–17.32)                     | 1.00    |
| Days in hospital post CS, median (IQR), d    | 4 (4–5)                  | 5 (4–5)              | 0 (0–0)                                 | .28                                   |         |
| Readmission within 6 weeks postpartum, N (%) | 0 (0%)                  | 1 (1.0)              | N/A                                     | N/A                                   | 1.00    |

CS = cesarean section, IQR = interquartile range, RBC = red blood cell, SD = standard deviation, VAS = visual analog scale.

1. Anemia: hemoglobin <110 g/L.
2. Puerperal morbidity: fever of 38°C and higher on any of the first 10 days (measured 4 times each day with an interval of more than 4 hours) following delivery exclusive of the first 24 hours.
3. Adjusted for maternal age, body mass index at delivery, gravidity, and multiple pregnancy.
There were some limitations in our work. First, placenta previa with suspected deep accreta overlying previous cesarean scar was excluded from this study because more invasive procedures and specialized management would be required in this scenario[24] and these women should be studied separately. The exclusion of these women could have partially explained our high successful rate and the limited puerperal morbidity. Second, only 3 centers participate in this trial and therefore may not be generalizable outside of this region. Third, the inclusion criteria of ‘bleeding continued’ were based on personal judgment and thus not standard. And, we did not assess longer term complications due to our relatively short follow-up duration.

In conclusion, intrauterine double-balloon catheter is an effective substitute for traditional gauze packing in the management of PPH following CD for placenta previa, and is associated with less blood loss in the process. If a balloon is not available, uterine gauze packing is still an effective measure that can be utilized to avoid other invasive surgical procedures.

Acknowledgments
All the double-balloon catheters used in the study were provided by the manufacturer free of charge. The manufacturer had no involvement in study design, data collection, data interpretation, or data analysis. We thank all the women and their families who consented to participate in the study. In addition, the study team thanks Professor TT Lao of the Chinese University of Hong Kong for help in revising the manuscript.

Author contributions
JW and YD contributed equally to this article. JW was responsible for data collection and project management. YD was responsible for the procedures, interpreted results and manuscript preparation. BX prepared randomized number envelopes and ran the statistical analysis. ZW, NG, HJ and YX were responsible for the procedures. YH made the contribution to the study design and reviewed the text. All the authors read and approved the final report.

References
[1] Oladapo OT, Adetoro OO, Ekele BA, et al. When getting there is not enough: a nationwide cross-sectional study of 998 maternal deaths and 1451 near-misses in public tertiary hospitals in a low-income country. BJOG 2016;123:928–38.
[2] van den Akker T, Brobbel C, Dekkers OM, et al. Prevalence, indications, risk indicators, and outcomes of emergency peripartum hysterectomy worldwide: a systematic review and meta-analysis. Obstet Gynecol 2016;128:1281–94.
[3]Govindappagari S, Wright JD, Ananth CV, et al. Risk of peripartum hysterectomy and centre hysterectomy and delivery volume. Obstet Gynecol 2016;128:1215–24.
[4] Zeng C, Yang M, Ding Y, et al. Placenta accreta spectrum disorder trends in the context of the universal two-child policy in China and the risk of hysterectomy. Int J Gynaecol Obstet 2018;140:312–8.
[5] Collins SL, Stevenson GN, Al-Khan A, et al. Three-dimensional power doppler ultrasoundography for diagnosing abnormally invasive placenta and quantifying the risk. Obstet Gynecol 2015;126:645–53.
[6] Ge J, Liao H, Duan L, et al. Uterine packing during cesarean section in the management of intractable haemorrhage in central placenta previa. Arch Gynecol Obstet 2012;285:285–9.
[7] Guo YN, Ma J, Wang XJ, et al. Does uterine gauze packing increase the risk of puerperal morbidity in the management of postpartum haemorrhage during caesarean section: a retrospective cohort study. Int J Clin Exp Med 2015;8:13740–7.
[8] Georgiou C. Balloon tamponade in the management of postpartum haemorrhage: a review. BJOG 2009;116:748–57.
[9] WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2012.
[10] Jauniaux E, Alfirevic Z, Bhde AG, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline no. 27a. BJOG 2019;126:e1–e48.
[11] Lo A, SrMarie P, Yadav P, et al. The impact of Bakri balloon tamponade on the rate of postpartum hysterectomy for uterine atony. J Matern Fetal Neonatal Med 2017;30:1163–6.
[12] Kapoor S, Svanesan K, Veersingham M, Bakri balloon - a cautionary tale. Eur J Obstet Gynecol Reprod Biol 2018;221:203–4.
[13] Yue YY, Gu N, Dai YM, et al. Clinical analysis of a new hemostatic balloon in treating postpartum haemorrhage caused by uterine inertia. Chin J Woman Child Health Res 2016;27:619–23. [Chinese].
[14] Uygur D, Altun Ensari T, Ozgu-Erdinc AS, et al. Successful use of BT-Cath® balloon tamponade in the management of postpartum haemorrhage due to placenta previa. Eur J Obstet Gynecol Reprod Biol 2014;181:223–8.
[15] Gronvall M, Tikkanen M, Tallberg E, et al. Management of postpartum haemorrhage with intrauterine balloon tamponade: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand 2013;92:433–8.
[16] Mathur M, Ng QJ, Tagore S. Use of Bakri balloon tamponade (BTT) for conservative management of postpartum haemorrhage: a tertiary referral centre case series. J Obstet Gynaecol 2018;38:66–70.
[17] Okaforni, Uigwu EO, Obis N, et al. Uterine packing in the management of complete placenta praevia. Niger J Med 2014;23:321–4.
[18] Committee on Practice Bulletins-obstetricsPractice bulletin no. 183: postpartum haemorrhage. Obstet Gynecol 2017;130:168–86.
[19] Revert M, Cottenet J, Raynal P, et al. Intrauterine balloon tamponade for management of severe postpartum haemorrhage in a perinatal network: a prospective cohort study. BJOG 2017;124:1255–62.
[20] Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical AssociationGuideline of prevention and treatment about postpartum haemorrhage (2014). Chin J Obstet Gynecol Obstet Gynecol 2017;49:641–6.
[21] Kandeel M, Sanad Z, Ellakwa H, et al. Management of postpartum haemorrhage with intrauterine balloon tamponade using a condom catheter in an Egyptian setting. Int J Gynaecol Obstet 2016;135:272–5.
[22] Soiyama H, Miyamoto M, Sasa H, et al. Effect of routine rapid insertion of Bakri balloon tamponade on reducing haemorrhage from placenta previa during and after cesarean section. Arch Gynecol Obstet 2017;296:469–74.
[23] Beckmann MM, Chaplin J. Bakri balloon during cesarean delivery for placenta previa. Int J Gynaecol Obstet 2014;124:118–22.
[24] Shamshirsaz AA, Fox KA, Erfani H, et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol 2017;216: 612.e1–612.e5.